Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Yuko Oya, Tatsuya Yoshida, Teppei Yamaguchi, Junichi Shimizu, Hiroaki Kuroda, Yoshitsugu Horio, Toyoaki Hida, Hirokazu Matsushita
Publikováno v:
Cancer Research. 80:5390-5390
Anti-PD-1 therapy has been the standard treatment for advanced NSCLC patients. Some patients show durable response, while there are cases that show rapid progression after initiation of ICI treatment, which leads to early death. Therefore, we need a
Autor:
Suresh S. Ramalingam, Hideo Saka, Myung-Ju Ahn, Helena Yu, Leora Horn, Toyoaki Hida, Mireille Cantarini, Remy Verheijen, Jonathan Wessen, Geoffrey Oxnard, Yuichiro Ohe
Publikováno v:
Cancer Research. 79:CT034-CT034
The EGFR T790M mutation is the most common cause of resistance in pts receiving a first or second-generation EGFR-TKI for EGFRm NSCLC. Other resistance mechanisms include upregulation of the RAS/RAF/MEK/ERK signaling pathway. The Phase Ib TATTON stud
Autor:
Takeshi Toyoda, Ayuko Sato, Hideki Murakami, Hidemi Ito, Hirotaka Osada, Tohru Tsujimura, Toyoaki Hida, Yutaka Kondo, Yasushi Yatabe, Makiko Fujii, Yasue Matsudaira, Hayao Nakanishi, Yoshitaka Sekido, Eisaku Kondo
Publikováno v:
Cancer Research. 72:3082-3082
Malignant mesothelioma (MM) arises from the serosal cells of the pleural, peritoneal and pericardial cavities with poor prognosis because of its frequent diagnosis in advanced stages. The primary cause of this disease has often been linked to asbesto